Abstract
Advanced maternal age (AMA) is a primary driver of infertility worldwide. This retrospective cohort study analyzed 45,743 fresh, autologous IVF cycles at a single high-volume center in China to quantify how diagnostic factors and clinical outcomes deteriorate with age. Results show significant increases in cycle cancellation rates and FSH levels alongside sharp declines in ovarian reserve markers (AFC, AMH) and live birth rates. Notably, the economic cost to achieve a single live birth increases nearly 40-fold for women over 45 compared to those under 35, highlighting a dramatic "economic cliff" in fertility treatment.
Introduction
As social and economic shifts lead more women to postpone childbirth, Advanced Maternal Age (AMA)—typically defined as 35 or older—has become a primary hurdle in reproductive medicine. In China, the transition from the one-child to the two-child policy has further increased the number of older women seeking In-vitro Fertilization (IVF). While the general decline in fertility with age is well-documented, many studies lack granular data on women in their 40s. This research provides a high-resolution look at how specific diagnostic markers and treatment outcomes shift year-by-year as women age.
Methods
The study utilized a massive real-world dataset of 45,743 fresh, autologous IVF cycles performed between January 2008 and September 2017 at the Jinjiang District Maternal and Child Health Hospital in Chengdu, China. Researchers stratified patients into three primary groups (<35, 35-41, and ≥42) and further subdivided the oldest cohort into single-year increments (42, 43, 44, and ≥45) to capture the rapid decline in reproductive viability. Key variables included ovarian reserve markers (Basic FSH, AFC, and AMH), cycle metrics (oocytes retrieved, fertilization rates), and clinical outcomes (pregnancy and live birth rates).
Results
The Ovarian Reserve "Fade" and Cancellation Trap
Diagnostic markers showed a clear, statistically significant deterioration with advancing age. Basic Follicle Stimulating Hormone (FSH) levels increased, while Antral Follicle Count (AFC) and Anti-Müllerian Hormone (AMH) plummeted. By age 44, the average AFC dropped to approximately 3, indicating a severely diminished egg supply.
One of the most significant findings was the cycle cancellation rate. For women under 35, approximately 39.4% of cycles were cancelled, often due to poor response to stimulation. For women ≥42, this jumped to 85.03%, and for those over 44, it reached 91.15%. This means the vast majority of older patients never reach the embryo transfer stage.
Clinical and Economic Outcomes
It wasn't just that older women produced fewer eggs; the eggs produced were less likely to result in a live birth. The mean number of retrieved oocytes dropped from 12.15 in the youngest group to just 2.95 in the ≥42 group. Consequently, live birth rates per cycle dropped from 34.52% in the youngest group to 7.06% at age 42, and essentially 0% for women aged 45 and 46 in this dataset.
While the cost of a single cycle actually decreases with age (because cycles are often cancelled early before expensive procedures occur), the cost per live birth explodes.
The mean cost to achieve one live birth was approximately 33,514 RMB for women under 35. For women ≥45, that estimated cost soared to 1,357,154 RMB—a prohibitive sum for the average family.
Discussion and Conclusion
This study highlights that while IVF technology has advanced, it cannot fully compensate for the biological decline of the ovarian reserve. The "economic cliff" observed in women over 42 suggests a critical need for better counseling regarding realistic expectations and the importance of seeking treatment earlier.
Limitations include the retrospective nature of the study and the simplified economic analysis which did not account for varying stimulation protocols. Future research should integrate more detailed medication cost data and compare these Chinese outcomes with international datasets to refine global guidance for AMA patients.
Summary updated